Post by JHam on Dec 26, 2014 14:30:21 GMT
Translated from Hebrew on Google translate. Looks like Phase 2a was a big success. Also looks like BCLI may list on the Tel Aviv Stock Exchange next year. New indication coming up in 2015 too (only Parkinson's and MS mentioned).
www.bizportal.co.il/biomed/news/article/399749
2014 was a difficult year on the stock exchange the life science sector. A series of important clinical trials failures caused a drop of almost 35% in a year biomed index - at a time when abroad flourishing sector. Those who still want to get in and get to the Tel Aviv Stock Exchange in 2015 is a stem cell
Breinstorm (3.85 + 6.06%)
(NYSE: BCLI) that thrives abroad and its main product is a treatment for patients with ALS muscle atrophy - a market of one billion dollars a year.
5 recommended stocks and 2015, you choose! And a prize worth. Click to vote
Breinstorm product called NurOwn and is based on technology classifying stem cells taken from bone marrow of the patient's own cells that support nerve cells. These cells are transplanted back into liquid spinal cord and muscles of the patient and secrete increased levels of proteins responsible for the growth and survival of nerve cells develop, retain mature nerve cells and the renewal of the interaction between nerves to muscles.
In the past year, the Company made a face lift. The entrepreneur behind the company life Leibovitz gave up the position of general manager and follow the appointment of an American company CEO - Tony Fyorino. Until the appointment of Fyorino Company operated mainly in its R & D center in Petah Tikva - Fyorino runs the company from the United States. Special interview to Bizportal talking Fyorino the coming year for the company which is supposed to be a year with many events.
The important experimental results - at the beginning of 2016
"2015 Lbereinstorm most important thing is to continue to perform the Phase 2 clinical trial," says Fyorino. "We expect to complete the recruitment of patients during the year. Then will take about six month follow-up and about in the first quarter of 2016 will be announced the results of the experiment."
The experiment Sbreinstorm editor is the largest trial to date made and is expected to have about 50 patients and is being conducted in several leading medical centers in the US. The estimated cost of the study is $ 2 million each quarter and for the company success in the experiment is critical for the benefit of future development.
For now this experiment Advanced - but investors Breinstorm awaiting the results of a smaller trial. In ten days - on January 5, more specifically the Company will publish clinical results in Phase 2a conducted among 26 patients with ALS. Interim results presented last June (related to 14 patients) have shown performance improvements of the disease and experimental results should strengthen these findings.
Another product clinic
Although the focus of Breinstorm is the treatment of ALS, Fyorino know that the company should not have a dependency on a single product and therefore works to expand the company's product portfolio based on stem cells. "The company has a lot of knowledge in the field of Parkinson's, MS, Department of Atkinson and others. We carried out experiments on animals and have the potential for other issues. One of my goals is to introduce another product coming year clinic".
At the same time, 2015 is likely to be one in which the company will also trade on the Tel Aviv. In June, the company raised from investors a total of $ 10.5 million and has made several moves that helped finance her objects and Nasdaq. Indeed, the company has not yet officially decided whether to register the shares for trading on the TASE well but Fyorino implying that "we discussed with our consultants decide when and whether the listing here. If we decide about it - I would expect this to happen in 2015 ".
Breinstorm is currently traded value of $ 55-60 million but Fyorino big believer her potential. "There are two key things that I found in. In terms of products - I got the chance to learn more about the clinical findings and the science behind the company. The second thing is the people - the company has amazing people and I'm excited every time to meet them when I come for a visit."
www.bizportal.co.il/biomed/news/article/399749
2014 was a difficult year on the stock exchange the life science sector. A series of important clinical trials failures caused a drop of almost 35% in a year biomed index - at a time when abroad flourishing sector. Those who still want to get in and get to the Tel Aviv Stock Exchange in 2015 is a stem cell
Breinstorm (3.85 + 6.06%)
(NYSE: BCLI) that thrives abroad and its main product is a treatment for patients with ALS muscle atrophy - a market of one billion dollars a year.
5 recommended stocks and 2015, you choose! And a prize worth. Click to vote
Breinstorm product called NurOwn and is based on technology classifying stem cells taken from bone marrow of the patient's own cells that support nerve cells. These cells are transplanted back into liquid spinal cord and muscles of the patient and secrete increased levels of proteins responsible for the growth and survival of nerve cells develop, retain mature nerve cells and the renewal of the interaction between nerves to muscles.
In the past year, the Company made a face lift. The entrepreneur behind the company life Leibovitz gave up the position of general manager and follow the appointment of an American company CEO - Tony Fyorino. Until the appointment of Fyorino Company operated mainly in its R & D center in Petah Tikva - Fyorino runs the company from the United States. Special interview to Bizportal talking Fyorino the coming year for the company which is supposed to be a year with many events.
The important experimental results - at the beginning of 2016
"2015 Lbereinstorm most important thing is to continue to perform the Phase 2 clinical trial," says Fyorino. "We expect to complete the recruitment of patients during the year. Then will take about six month follow-up and about in the first quarter of 2016 will be announced the results of the experiment."
The experiment Sbreinstorm editor is the largest trial to date made and is expected to have about 50 patients and is being conducted in several leading medical centers in the US. The estimated cost of the study is $ 2 million each quarter and for the company success in the experiment is critical for the benefit of future development.
For now this experiment Advanced - but investors Breinstorm awaiting the results of a smaller trial. In ten days - on January 5, more specifically the Company will publish clinical results in Phase 2a conducted among 26 patients with ALS. Interim results presented last June (related to 14 patients) have shown performance improvements of the disease and experimental results should strengthen these findings.
Another product clinic
Although the focus of Breinstorm is the treatment of ALS, Fyorino know that the company should not have a dependency on a single product and therefore works to expand the company's product portfolio based on stem cells. "The company has a lot of knowledge in the field of Parkinson's, MS, Department of Atkinson and others. We carried out experiments on animals and have the potential for other issues. One of my goals is to introduce another product coming year clinic".
At the same time, 2015 is likely to be one in which the company will also trade on the Tel Aviv. In June, the company raised from investors a total of $ 10.5 million and has made several moves that helped finance her objects and Nasdaq. Indeed, the company has not yet officially decided whether to register the shares for trading on the TASE well but Fyorino implying that "we discussed with our consultants decide when and whether the listing here. If we decide about it - I would expect this to happen in 2015 ".
Breinstorm is currently traded value of $ 55-60 million but Fyorino big believer her potential. "There are two key things that I found in. In terms of products - I got the chance to learn more about the clinical findings and the science behind the company. The second thing is the people - the company has amazing people and I'm excited every time to meet them when I come for a visit."
